Who is tested for diabetic kidney disease and who initiates treatment? The Translating Research Into Action for Diabetes (TRIAD) study

Diabetes Care

Volumn 29, Issue 8, 2006, Pages 1733-1738

  Johnson, Susan L ^a   Tierney, Edward F ^b   Onyemere, Kingsley U ^a   Tseng, Chien Wen ^c   Safford, Monica M ^d   Karter, Andrew J ^e   Ferrara, Assiamira ^e   Duru, O Kenrick ^f   Brown, Arleen F ^f   Narayan, K M Venkat ^b   Thompson, Theodore J ^b   Herman, William H ^a,g  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^c PACIFIC HEALTH RESEARCH INSTITUTE   (United States)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^e DIVISION OF RESEARCH   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ALBUMINURIA; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; HYPERLIPIDEMIA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PATIENT CARE; PERIPHERAL NEUROPATHY; PREVALENCE; PROSPECTIVE STUDY; RENAL DIABETES; RISK FACTOR; SCREENING TEST; SYSTOLIC BLOOD PRESSURE;

ALBUMINURIA; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CROSS-SECTIONAL STUDIES; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; RISK FACTORS;

EID: 33746639953     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-0260     Document Type: Article

References (27)

1. Krolewski AS, Warram JH, Freire MB: Epidemiology of late diabetic complications: a basis for the development and evaluation of preventive programs. Endocrinol Metab Clin North Am 25:217-242, 1996
2. Centers for Disease Control and Prevention: National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2003. Revised ed. Atlanta, GA, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2004
3. Hogan P, Dall T, Nikolov P, the American Diabetes Association: Economic costs of diabetes in the U.S. in 2002. Diabetes Care 26:917-932, 2003
4. Bakris G, Williams M, Dwarkin L, Elliot W, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J: Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 36:646-661, 2000
5. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118:577-581, 1993
6. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med 329:1456-1462, 1993
7. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, the Collaborative Study Group: Renoprotective effect of angiotensin-receptor antagonist irbesartan in pateints with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
8. Brenner BM, Cooper ME, de Zeeuw D, Keanne WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, the RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropthy. N Engl J Med 345:861-869, 2001
9. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
10. Viberti G, Wheeldon NM: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 106:672-678, 2002
11. American Diabetes Association: Nephropathy in diabetes. Diabetes Care 27 (Suppl. 1):S79-S83, 2004
12. Kraft SK, Lazaridis EN, Qiu C, Clark CM Jr, Marrero DG: Screening and treatment of diabetic nephropathy by primary care physicians. J Gen Intern Med 14:88-97, 1999
13. Mainous AG 3rd, Gill JM: The lack of screening for diabetic nephropathy: evidence from a privately insured population. Fam Med 33:115-119, 2001
14. The State of Health Care Quality: 2003 [article online], 2003. Available from http://www.ncqa.org/Communications/State%20Of%20Managed%20Care/ SOHCREPORT2003.pdf. Accessed 24 January 2006
15. Sikka R, Waters J, Moore W, Sutton D, Herman WH, Aubert RE: Renal assessment practices and the effect of nurse case management of health maintenance organization patients with diabetes. Diabetes Care 22:1-6, 1999
16. The TRIAD Study Group: The Translating Research into Action for Diabetes (TRIAD) study: a multicenter study of diabetes in managed care. Diabetes Care 25:386-389, 2002
17. Frankel L: The report of the CASRO Task Force on response rates. In Improving Data Quality in a Sample Survey. Cambridge, MA, Marketing Science Institute, 1983, p. 1-11
18. Herman WH, Hawthorne V, Hamman RF, Keen H, DeFronzo RA, Newman J, DeStefano F: Consensus statement: preventing the kidney disease of diabetes mellitus: public health perspectives. Am J Kidney Dis 13:2-6, 1989
19. Ritz E: Nephropathy in type 2 diabetes. J Intern Med 245:111-126, 1999
20. Brown AF, Mangione CM, Saliba D, Sarkisian CA: Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 51:S265-S280, 2003
21. Centers for Disease Control and Prevention: United States life tables, 2002. Available from http://www.cdc.gov/nchs/data/dvs/life2002.pdf [article online]. Accessed 24 January 2006
22. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial: the Losartan Heart Failure Survival Study ELITE II. Lancet 355:1582-1587, 2000
23. Lacourciere Y: A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension. Clin Ther 22:1213-1224, 2000
24. Hueston WJ, Scibelli S, Mainous IA: Use of microalbuminuria testing in persons with type 2 diabetes: are the right patients being tested? J Fam Pract 50:669-673, 2001
25. American Diabetes Association: Standards of medical care in diabetes. Diabetes Care 27 (Suppl. 1):S15-S35, 2004
26. Rosen AB, Karter AJ, Liu JY, Selby JV, Schneider EC: Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk clinical and ethnic groups with diabetes. J Gen Intern Med 19:669-675, 2004
27. Elliott WJ, Maddy R, Toto R, Baris G: Hypertension in patients with diabetes: overcoming barriers to effective control. Postgrad Med 107:29-38, 2000